Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00612885 |
This PMS study aims to review the followings by investigating the actual practice of MicardisPlus Tablet on the market:
Study Type: | Observational |
Official Title: | Regulatory Drug Safety Survey |
Ages Eligible for Study: | 15 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
diagnosed as osteoarthritis and rheumatoid arthritis
EXCLUSION CRITERIA:
Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Busan, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Chungbuk, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Daegu, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Daejeon, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Gangwondo, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Seoul, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Gyeongbuk, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Gyeonggido, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Gyeongnam, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Jeonnam, Korea, Republic of | |
Boehringer Ingelheim Investigational Site | |
Gwangju, Korea, Republic of |
Study Chair: | Boehringer Ingelheim Study Coordinator | B.I. Korea Ltd. |
Study ID Numbers: | 107.270 |
Study First Received: | January 30, 2008 |
Last Updated: | June 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00612885 |
Health Authority: | Korea, Republic of: KOREA Food and Drug Administration (KFDA) |
Autoimmune Diseases Musculoskeletal Diseases Osteoarthritis Joint Diseases Arthritis |
Meloxicam Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases |
Immune System Diseases |